NRX Pharmaceuticals, Inc.(NRXP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

NRX Pharmaceuticals, Inc. (NRXP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRXP at 21.0/100 on a 32-signal composite quality model, placing it at rank #2,771 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NRX Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-16.5M. Top institutional holders of NRXP by reported 13-F value include B Group, VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL, based on the most recent SEC filings. NRXP trades on the Nasdaq exchange and files with the SEC under CIK 1719406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRX Pharmaceuticals, Inc. directly from SEC EDGAR.